A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday, late-stage results that could propel the next-generation treatment onto the market.
The drug, orforglipron, produced results that were nearly comparable to the benefits of available GLP-1 drugs, which are primarily weekly injectable treatments. Companies have been racing to develop more convenient, as well as more powerful, obesity treatments, including pills. The thought is that the easier-to-take medicines could give companies an edge in the competitive marketplace and expand their patient bases.
Shares of Lilly surged in pre-market trading Thursday.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
